Related Experiment Video

Updated: Mar 24, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K

Pediatric Myasthenia Gravis

Andrew F Fischer1, Jason H Peragallo

  • 1Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA.

International Ophthalmology Clinics
|March 23, 2026
PubMed

Insights

Pediatric myasthenia gravis, a neuromuscular junction disorder, presents with fatigable weakness. Diagnosis involves clinical, serologic, and electrophysiologic studies, with management including medications and thymectomy for juvenile cases.

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Pediatric myasthenia gravis is a group of disorders affecting neuromuscular junction transmission.
  • It causes fatigable weakness, potentially impacting respiration.
  • Three subtypes exist: transient neonatal myasthenia, congenital myasthenic syndromes, and juvenile myasthenia gravis.

Purpose of the Study:

  • To outline the diagnostic approaches and management strategies for pediatric myasthenia gravis.
  • To differentiate between the subtypes of pediatric myasthenia gravis.
  • To highlight the importance of managing ophthalmic complications.

Main Methods:

  • Clinical evaluation.
  • Serologic studies.
  • Electrophysiologic studies.

Main Results:

  • Diagnosis relies on a combination of clinical, serologic, and electrophysiologic findings.
  • Management involves acetylcholinesterase inhibitors, immunosuppressive agents, thymectomy (for JMG), IVIG, and PLEX for exacerbations.
  • Ophthalmic complications like strabismus and ptosis require management to prevent amblyopia.

Conclusions:

  • Pediatric myasthenia gravis is a complex condition with distinct subtypes.
  • Comprehensive diagnostic evaluation is crucial for appropriate treatment.
  • Multifaceted management, including medical therapy and surgical options, is essential for optimal outcomes and preventing vision loss.

Keywords:
gravismyastheniapediatric

More Related Videos

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

25.9K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.9K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.1K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.3K
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.4K
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
322